Drug intelligence / Profile preview

SGA305

Development stage: Preclinical
Lead developer: BMG Pharma
Administration: Intradermal

Overview

SGA305 is an injectable dermal filler being developed by BMG Pharma for applications in aesthetic medicine. It is specifically designed for deep dermis injection to provide structural support and volume restoration. The product is currently in the preclinical stage of development.

Other names: SGA305 Filler Deep DermisSGA-305 Filler Deep DermisSGA 305 Filler Deep Dermis

Targets

MesothelinCD3 (T-cell surface glycoprotein CD3)CDH3 (Cadherin-3)

Beyond the preview

Go deeper on SGA305.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SGA305.

Explore the full profile